UNSPSC 51334001: Fluspirilene

This classification denotes an antipsychotic agent and dopamine antagonist with the molecular formula C29H31F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C5QA4GLR9M, chemically known as 1,3,8-triazaspiro(4.5)decan-4-one, 8-(4,4-bis(4-fluorophenyl)butyl)-1-phenyl- but generally known as fluspirilene, which bears US NIH Compound Identifier 3396. European Medicines Agency schedules Fluspirilene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07755MIG.

UNSPSC 51334001 Fluspirilene is a Commodity code, yet the recent state and local opportunities posted under it bear no connection to fluspirilene itself — an antipsychotic medication used in psychiatric treatment. Instead, the three most recent solicitations tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing. The code shows a clear mismatch between its nominal scope and actual buying activity, suggesting either a tagging error in source systems or a drift in how this code is being applied in practice. State and local governments are buying naloxone in volume (Seminole County, Florida sought 1,900 units annually), exploring innovative pharmacy benefit program models (Texas HHS Commission), and sourcing generic and OTC medications through multi-state cooperative agreements (Minnesota Multistate Cooperative Purchasing Alliance). The issuing bodies span county health departments, state health agencies, and multi-state cooperative purchasing organizations; there are no standout repeat buyers in the recent record, but the cooperative purchasing vehicle (MMCAP) appears to aggregate demand across multiple participating jurisdictions including Oregon.

Activity is concentrated in the South and Upper Midwest. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023, a date that appears to be a data error in the source) for naloxone and drug deactivation systems with quarterly deliveries to the county's Community Health Building. The Texas Health and Human Services Commission issued an RFI in early April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment models before issuing a formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP in January 2026 (responses due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract term of two years and performance penalties of $200 to $1,500 per violation. Given the apparent mismatch between the code's pharmaceutical scope and the actual buying activity in the recent record, firms should verify code alignment before pursuing opportunities tagged to 51334001.